A Study for Patients With Acute Leukemia

Status Terminated

Clinical Trial Summary

This study is a multicenter, nonrandomized, open-label, dose-escalation with intra-patient dose-escalation, Phase 1 study of intravenous LY2523355 to determine the dose of LY2523355 that can be safely administered to participants with acute leukemia. Part A and Part B are dose escalation of two schedules in participants with acute leukemia. Parts A and B will enroll concurrently. Part C is a dose expansion for each schedule in participants with acute myeloblastic leukemia (AML).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01214655
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Terminated
Phase	Phase 1
Start date	June 2008
Completion date	February 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05088356` - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft	Phase 1
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Recruiting	`NCT04969601` - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings	Phase 1/Phase 2
Recruiting	`NCT02356159` - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation	Phase 1/Phase 2
Withdrawn	`NCT05170828` - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies	Phase 1
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Active, not recruiting	`NCT01956630` - Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT	Phase 1/Phase 2
Completed	`NCT00988013` - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies	N/A
Enrolling by invitation	`NCT01728402` - Pathogenesis of Hematologic Malignancies
Active, not recruiting	`NCT03595800` - Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen	Phase 3
Completed	`NCT02440178` - Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia	Phase 2
Recruiting	`NCT05071482` - Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL	Phase 4
Completed	`NCT03042676` - Electronic Database for the Follow up of the ATG_FamilyStudy
Withdrawn	`NCT03138395` - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML	N/A
Completed	`NCT04597086` - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients	N/A
Terminated	`NCT03588936` - Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant	Phase 1
Recruiting	`NCT05521204` - Olverembatinib for FGFR1-rearranged Neoplasms	Phase 2
Not yet recruiting	`NCT04084327` - Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1
Not yet recruiting	`NCT06026839` - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors